COVID-19 Vaccine Safety and Efficacy in Multiple Sclerosis and Other Neuroimmunological Diseases
COVID-19 Vaccine Biomarker Study in Multiple Sclerosis and Other Neuroimmunological Diseases
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAT5674
Contact: Adelle Ricci: 212-305-2434 / mscenter_neuro@cumc.columbia.edu
Additional Study Information: We need your help today to gather information about the experience of patients with autoimmune diseases of the central nervous system (multiple sclerosis (MS), neuromyelitis optica (NMO), and antiMOG associated disease (MOGAD)) in regards to COVID19 vaccines. Because individuals with MS, NMO, and MOGAD were not included in the COVID19 vaccine trials, we want to learn more about the experience of individuals with these autoimmune diseases and the vaccine. Because many patients with central nervous system autoimmune disease also take medications that affect the immune system, we want to find out whether these medications affect how the immune system responds to the vaccine and whether the efficacy of the vaccine is affected.
Investigator
Rebecca Straus Farber, MD
Do You Qualify?
Do you have MS, NMO, or MOGAD? Yes No
Do you plan on getting the COVID-19 vaccine in the future? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Adelle Ricci
mscenter_neuro@cumc.columbia.edu
212-305-2434